

## AMENDMENTS

### IN THE CLAIMS

Claims 1-42 (canceled).

(Please enter the following new claims:)

43. (Currently Amended) A method of treating a host suffering from a ~~condition~~ characterized by an ~~undesirable increase in synaptic responsiveness~~ epilepsy, said method comprising:

administering to said host an amount of a serine protease inhibitor effective to treat said host for said epilepsy ~~condition~~.

44. (Canceled)

45. (Canceled).

46. (Previously presented) The method according to Claim 43, wherein said method results in a decrease in seizure proneness.

47. (Previously presented) The method according to Claim 43, wherein said host is a mammalian host.

48. (Canceled).

49. (Canceled).

50. (Canceled).

51. (Currently Amended)

A method of preventing the onset of epilepsy a

~~condition characterized by increased synaptic responsiveness in a host~~, which method comprises:

administering to said host an amount of a serine protease inhibitor effective to prevent onset of said epilepsy condition.

52. (Canceled)

53. (Canceled)

*D1*  
*cont.*  
54. (Previously presented) The method according to Claim 51, wherein said host is a mammalian host.

---

✓  
Please add the following new claims:

---

--55. (New) The method of Claim 43, wherein said serine protease inhibitor is an inhibitor of trypsin-like serine proteases.

*D2*  
56. (New) The method of Claim 55, wherein serine protease inhibitor is a tPA inhibitor.

57. (New) The method of Claim 51, wherein said serine protease inhibitor is an inhibitor of trypsin-like serine proteases.

58. (New) The method of Claim 57, wherein serine protease inhibitor is a tPA inhibitor. --

---